# JNJ-79635322

Source: https://onco.cc/drugs/jnj-79635322/  
OnCo record `jnj-79635322` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

JNJ-79635322 is an experimental investigational agent whose form is not stated in the registry from Janssen Research & Development in phase 3 trials for multiple myeloma, with its target not yet stated publicly.

## Summary

JNJ-79635322 is an investigational agent whose form is not stated in the registry developed by Janssen Research & Development. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: JNJ-79635322 will be administered as SC injection. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07258511 (A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma) and NCT07518186 (A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma), in multiple myeloma. The largest, NCT07518186, plans to enrol 700 participants with primary completion expected 2029-04-29. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: trispecific antibody (BCMA x GPRC5D x CD3, per the sponsor's pipeline page; form not stated in the registry record)
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of JNJ-79635322: https://clinicaltrials.gov/search?intr=JNJ-79635322

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)
- trials: [A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct07258511/), [A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct07518186/), [A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relaps](https://onco.cc/trials/nct07589634/), [A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct07266441/)

---
JSON: https://onco.cc/api/v1/entities/jnj-79635322.json